⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

KTTA News

Pasithea Therapeutics Corp. Common Stock

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients